Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT78R5H)

• DTT Name: Heat shock protein 90 alpha (HSP90A) DTT Info
• Gene Name: HSP90AA1

Molecule-Related Drug & Molecule List

2 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amlexanox	DM0DQM5	Respiratory tract inflammation	CA07	Approved	[1]
Cromoglicate	DM74LZK	Asthma	CA23	Approved	[1]

14 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BIIB-021	DMPAJ41	Breast cancer	2C60-2C65	Phase 2	[2]
Efungumab	DMBHP56	Breast cancer	2C60-2C65	Phase 2	[3]
KW-2478	DMJGL72	Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]
NVP-AUY922	DMTYXQF	Multiple myeloma	2A83	Phase 2	[5]
Tanespimycin	DMNLQHK	Breast cancer	2C60-2C65	Phase 2	[6]
VER 50589	DMFLZPC	Breast cancer	2C60-2C65	Phase 2	[5]
SNX-5422	DMIU0VP	Haematological malignancy	2B33.Y	Phase 1/2	[7]
Alvespimycin hydrochloride	DM6KU93	Ovarian cancer	2C73	Phase 1	[8]
AT13387	DM2B9E0	Melanoma	2C30	Phase 1	[9]
BIIB 028	DMTRF71	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
Debio 0932	DMWP3G1	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]
PU-AD	DMKSU35	Encephalopathy	8E47	Phase 1	[12]
PU3	DMJO0BP	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
RTA-901	DM7C062	Diabetic neuropathy	8C0Z	Phase 1	[12]

4 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
HBP-347	DMX3IRE	Autoimmune diabetes	5A10	Discontinued in Phase 3	[13]
Geldanamycin	DMS7TC5	Kidney cancer	2C90.0	Discontinued in Phase 2	[14]
IPI-493	DMCF0XK	Gastric adenocarcinoma	2B72	Discontinued in Phase 1	[15]
EC-154	DM5ITJF	Solid tumour/cancer	2A00-2F9Z	Terminated	[17]

2 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CCT-018159	DM065ZH	Solid tumour/cancer	2A00-2F9Z	Preclinical	[5]
KOS-2484	DMXY81K	Solid tumour/cancer	2A00-2F9Z	Preclinical	[16]

18 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
17-desmethoxy-17-aminogeldanamycin	DMCALYO	Discovery agent	N.A.	Investigative	[18]
2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol	DMUY75A	Discovery agent	N.A.	Investigative	[19]
2-Methyl-2,4-Pentanediol	DMD45CU	Discovery agent	N.A.	Investigative	[20]
4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine	DM9WQOJ	Discovery agent	N.A.	Investigative	[19]
6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE	DM89LF5	Discovery agent	N.A.	Investigative	[19]
8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-	DMT8QAP	Discovery agent	N.A.	Investigative	[19]
9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine	DMXU90T	Discovery agent	N.A.	Investigative	[19]
9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine	DMKHPAE	Discovery agent	N.A.	Investigative	[19]
Geldanamycin-estradiol hybrid	DMUSJ96	Discovery agent	N.A.	Investigative	[21]
GNF-PF-67	DM3SYH5	Discovery agent	N.A.	Investigative	[22]
KOSN1559	DM1SKNP	Solid tumour/cancer	2A00-2F9Z	Investigative	[5]
Macbecin	DMDLF0J	Solid tumour/cancer	2A00-2F9Z	Investigative	[5]
PU24S	DMHAJC1	Solid tumour/cancer	2A00-2F9Z	Investigative	[5]
Radicicol	DMNZS94	Discovery agent	N.A.	Investigative	[23]
RHEIN	DMS6IJ0	Discovery agent	N.A.	Investigative	[22]
SNX-2112	DMB5A80	Discovery agent	N.A.	Investigative	[18]
VER-49009	DMF1KDX	Discovery agent	N.A.	Investigative	[24]
ZEARALANONE	DMI5WF1	Discovery agent	N.A.	Investigative	[22]

References

• [1] Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41.
• [2] BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 2009 Apr;8(4):921-9.
• [3] Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother. 2009 Nov;43(11):1818-23.
• [4] Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J. 2012 Apr;2(4):e68.
• [5] Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
• [6] Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin Investig Drugs. 2009 Jun;18(6):861-8.
• [7] SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hema... Blood. 2009 Jan 22;113(4):846-55.
• [8] Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jul;51(1):34-41.
• [9] Astex Presents Updates on AT13387, its HSP90 Inhibitor, and AT9283, its Multi-Targeted Kinase Inhibitor at the EORTC-NCI-AACR Cancer Conference. Astex. 2008.
• [10] Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res. 2013 Sep 1;19(17):4824-31.
• [11] Clinical pipeline report, company report or official report of Debiopharm (2011).
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] US patent application no. 2013,0023,420, Susceptibility to hsp90-inhibitors.
• [14] Heat shock protein 90 regulates the stability of MEKK3 in HEK293 cells. Cell Immunol. 2009;259(1):49-55.
• [15] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [16] US patent application no. 2014,0079,636, Targeted therapeutics.
• [17] WO patent application no. 2013,1734,36, Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitor based on hypoxic status.
• [18] Heat shock protein 90: inhibitors in clinical trials. J Med Chem. 2010 Jan 14;53(1):3-17.
• [19] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [20] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [21] Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8.
• [22] In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
• [23] High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal Biochem. 2004 Apr 15;327(2):176-83.
• [24] Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem. 2005 Jun 30;48(13):4212-5.